ArticlePloS one2026
Dynamic platelet profiles in the emergency department and their predictive value for 28-day all-cause mortality in septic patients.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis is a significant cause of global mortality and most frequently first presents in the emergency department. Dynamic platelet changes play a key pathophysiological role in sepsis, yet their comprehensive prognostic value-particularly from a multi-dimensional perspective that includes value, magnitude, and timing-remains underexplored.
methodsIn this retrospective cohort study, 363 episodes of sepsis first diagnosed in the emergency department of Beijing Aviation General Hospital between April 2020 and January 2025 were included. We systematically analyzed three dimensions of platelet counts: 1) nadir value; 2) the magnitude of platelet decline; 3) dynamic timing (time to nadir and maximum decline). Multivariable Cox regression models were used to assess their independent associations with 28-day all-cause mortality, adjusting for demographics, comorbidities, infection characteristics, and disease severity.
resultsAmong 363 patients (median age 81 years, 54.5% male), the 28-day mortality rate was 39.9%. Compared to survivors, non-survivors had a lower platelet nadir [70.0 vs. 134 × 10⁹/L, p < 0.001] and a greater magnitude of platelet decline [62.8% vs. 31.5%, p < 0.001].Multivariable analysis revealed dose-response relationships for platelet nadir (moderate [50-99 × 10⁹/L]: aHR = 2.04, p = 0.014; severe [20-49 × 10⁹/L]: aHR = 2.98, p < 0.001; profound [<20 × 10⁹/L]: aHR = 3.46, p = 0.003) and magnitude of decline (moderate [30-50%]: aHR = 1.79, p = 0.044; severe [>50%]: aHR = 2.43, p < 0.001). Timing analysis demonstrated that intermediate and late platelet nadir were associated with higher mortality risk (intermediate: aHR = 4.39-7.28, all p < 0.001; late: aHR = 5.85-9.58, all p < 0.001), while initial and early nadir showed no significant association. Similarly, both intermediate and late maximum platelet decline were associated with increased mortality (intermediate: aHR = 2.70-2.98, all p < 0.001; late: aHR = 6.33-6.87, all p < 0.001).
conclusionThrough stepwise analysis, we demonstrate that dynamic platelet parameters-magnitude and timing of decline-independently predict 28-day mortality in sepsis. The magnitude applies to all patients but is static, while timing adds a critical dimension: the same degree of decline has different prognostic implications depending on when it occurs. Delayed decline and intermediate/late nadir indicate poor prognosis, whereas early nadir does not. These findings underscore the importance of longitudinal platelet monitoring in the emergency setting, as the trajectory-integrating both magnitude and timing-identifies at-risk patients, including those without thrombocytopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.